No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation
Preface
Practices in the Prevention of Venous Thromboembolism
Prothrombotic Consequences of the Oxidation of Fibrinogen and their Inhibition by Aspirin
Anticoagulation Management as a Risk Factor for Adverse Events
Effects of Recombinant Human Megakaryocyte Growth and Development Factor (rHuMGDF) on Platelet Production, Platelet Aggregation, and Thrombosis
Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease
Glucose-Insulin-Potassium Does Not Reduce Myocardial Infarct Size in an Ischemic/Reperfusion Rabbit Model
Patient Self-Management of Oral Anticoagulant Therapy
Survival in Acute Myocardial Infarction Induced by Coronary Ligation
Outpatient Therapy of Deep Vein Thrombosis
Crossreactivity of Human versus Swine Platelet Surface Antigens Is Similar for Glycoproteins Ib and IIIa, but Not for the Glycoprotein IIb/IIIa Complex
Platelet Inhibition in Cardiovascular Disease Management
Evaluation of Hypercoagulable States
Antithrombotic Therapy in Stroke Prevention and Treatment
A Randomized, Blinded Study of Two Doses of Novastan® (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction
The View from the Inside
The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial
Workshop
Fibrinogen–Just a Protein?
Workshop
Guidelines for the management of Patients with Acute Myocardial Infarction
Workshop
Abstracts
Platelet Activity in the Early Stage of Acute Myocardial Infarction
The Laboratory of Coagulation A review of present laboratory techniques